THCB is excited to present “Measured Outcomes.” This short film featuring Michael Porter and a cast of international experts may be the best discussion of where value-based care is headed that you will ever see.
THCB congratulates underwriter @HealthCatalyst for producing an amazing film.
“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has,” goes the quotation usually attributed to the late anthropologist Margaret Mead. Today, huddled around conference tablesand hatching ambitious plans, relatively small groups of committed leaders are trying to improve health and transform health care in their communities.
Consider these examples:
A basic rule of scientific discovery is that the answers you get are only as good as the questions you ask.
That is certainly the case in health care. Traditionally, it has been the sole responsibility of health researchers to develop questions for study that, when answered, can provide reliable and relevant information for patients and clinicians. For the most part, they’ve done an exceptional job, as evidenced by countless discoveries about the nature of disease and remarkable advances in diagnosing, preventing and treating them. But when researchers are the only ones determining scientific inquiry, other critical perspectives can be missed – most notably, the practical, frequent questions asked by patients, caregivers and clinicians about the best choice among two or more for options that are available.
But what if we tried something different – still soliciting the best ideas for studies from the research community but focusing on questions most important to patients, their families, clinicians and other healthcare stakeholders not traditionally involved in the research process? What if we then brought those same stakeholders, plus top scientists, into the room where proposals to study those questions are judged? What if we also sought to make them partners on the research teams that design and conduct the studies and help get the word out on results that could improve care and outcomes?
A long, long time ago, hospitals existed to admit patients when they were sick, treat them with medicines or surgery and good nursing care, and discharge them after they became well.
Hospital care was at one time a charity, which evolved into a nonprofit service, before it became a Very Big Business.
In olden days, nonprofit hospitals charged patients straightforward fees for their services. Then, when you were just a young whippersnapper or perhaps merely a gleam in your father’s eyes, Medicare and Big Insurance started collecting premiums from workers and dole it out to hospitals when the workers or retirees needed hospital care.
At that point, hospital fees became confusing. The people who received care didn’t see what the charges were, and the payers didn’t really know how much care was medically necessary or even actually delivered by the increasingly profit-driven hospitals, let alone how much it cost to provide those services.
The NIH (National Institutes of Health) recently released initial results from its SPRINT (Systolic Blood Pressure Intervention Trial) study, suggesting more aggressive treatment for hypertension may reduce risk for cardiovascular events by 30 percent and the risk of death by 25 percent.
The SPRINT group recruited over 9,000 non-diabetic subjects aged 50 or older with systolic blood pressure (SBP) over 130. Individuals were then randomly assigned to either a standard treatment goal of lowering SBP below 140 or a more intensive treatment goal of lowering SBP below 120. The findings were sufficiently compelling that results were released more than a year in advance of the study’s planned conclusion.
While the SPRINT researchers have only released very high level findings, the general sentiment appears to be supportive of releasing this information early as the New York Times Op-Ed by Eric Topol, MD, so rightly notes. However, the lack of detail has generated sharp questions on several issues, including whether a reduction of cardiovascular risk by 30 percent actually translates into substantial numbers of individuals affected, potential side effects of increasing the number of medications, and general caution regarding findings released before peer reviewed publication.
I’m working on a long piece about Sharecare. Today at Health 2.0 my partner Indu Subaiya will be interviewing Jeff Arnold CEO of Sharecare about the progress they’ve made in the 5 years since he launched the company on stage at Health 2.0 in 2010.
Just to give you a little taster, I’m posting an interview with one of Sharecare’s clients and investors, the big Catholic hospital chain Trinity. I think this interview with Bret Gallaway at Trinity will whet your appetite for Jeff today and the longer article coming shortly. But it’s a great story about what is now a major platform for consumer health.
Back in August, 2015 IBM announced their bid to acquire Merge Healthcare for $1B dollars. (Forbes article here) Merge is a product that helps to manage, store, report, and bill for the medical images of patients as read by Radiologists. (More here) Today between the 7500 Merge customers they have access to roughly 30 billion images.
The promise for Watson Health is to learn how to “see” through machine learning from the vast amount of medical images that Merge Healthcare manages. Currently, Watson reads 66 million pages a second. It is predicted by IBM researchers that 90% of all “Big Data” stored by healthcare systems is related to medical imaging.
The offer to hospitals, healthcare systems, Radiologists, and ultimately patients is that Watson will be able to have information, including medical images, uploaded to the cloud for analysis. Based on the symptoms and a cross referencing of medical images against images of previously diagnosed medical conditions and diseases, Watson would be able to provide an initial recommendation. (supporting article)
There has been at least one report that the Federal Trade Commission (“FTC”) is looking into anti-competitive practices based on the Texas Medical Board’s telemedicine regulations.
As a telemedicine company operating in Texas, we maintain that the rules put in place by the Texas Medical Board are by no means insurmountable and do not seriously limit competition. The rules merely allow better integration of telemedicine offerings with existing medical services and help ensure a better patient experience.
Telemedicine is possible in Texas as defined by the guidelines of The Texas Medical Board (TMB), but it has to be telemedicine done right. Telemedicine must be provided in a way which conforms with modern clinical safety standards, including ensuring continuity between traditional care encounters and telemedicine encounters.
The TMB regulations mandate that:
1. An individual must have a face-to-face visit with the provider group providing virtual care to establish a doctor/patient relationship;
2. Doctors treating a panel of patients virtually must have reciprocity (communication, accountability) with each other and should be under common medical direction; and
3. Physicians engaging in telemedicine must be able to follow-up with patients and vice versa.
Big news from perennial Health 2.0 favorite Healthline. The fast growing consumer destination site is spinning off a new subsidiary aimed at the market of provider-side analytics. Here’s a quick announcement of the news from CEO Dean Stephens
One of the most insightful and funniest writers in health care is recovering VC Lisa Suennen. With trusty sidekick Dave Shaywitz, she’s been doing Tech Tonics, one of these newly trendy (again) podcasts. And Sunday at Health 2.0 they interviewed my partner Indu Subaiya, and me. Want to know a little more aobut the backstory of Health 2.0? Listen in!
THCB's Podcasts
Listen to them on Itunes or Spotify
